MILESTONE PHARMACEUTICALS IN (MIST) Stock Price, Forecast & Analysis
USA - NASDAQ:MIST - CA59935V1076 - Common Stock
MIST Key Statistics, Chart & Performance
The current stock price of MIST is 2.06 USD. In the past month the price increased by 3.09%. In the past year, price increased by 17.65%.
MIST Latest News, Press Relases and Analysis
MIST Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| LLY | ELI LILLY & CO | 45.82 | 953.74B | ||
| JNJ | JOHNSON & JOHNSON | 18.89 | 472.30B | ||
| MRK | MERCK & CO. INC. | 10.58 | 232.74B | ||
| PFE | PFIZER INC | 7.84 | 142.65B | ||
| BMY | BRISTOL-MYERS SQUIBB CO | 7.13 | 95.24B | ||
| ZTS | ZOETIS INC | 19.07 | 53.59B | ||
| RPRX | ROYALTY PHARMA PLC- CL A | 9.51 | 22.80B | ||
| VTRS | VIATRIS INC | 4.63 | 12.57B | ||
| ELAN | ELANCO ANIMAL HEALTH INC | 21.84 | 10.42B | ||
| CORT | CORCEPT THERAPEUTICS INC | 85.84 | 7.96B | ||
| AXSM | AXSOME THERAPEUTICS INC | N/A | 7.00B | ||
| BLTE | BELITE BIO INC - ADR | N/A | 4.13B |
Related stock screener links
About MIST
Company Profile
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
Company Info
MILESTONE PHARMACEUTICALS IN
420-1111 boul. Dr.-Frederik-Philips
MONTREAL QUEBEC H4M 2X6 CA
CEO: Joseph Oliveto
Employees: 33
Phone: 15143360444
MILESTONE PHARMACEUTICALS IN / MIST FAQ
What does MILESTONE PHARMACEUTICALS IN do?
Milestone Pharmaceuticals, Inc. engages in the development and commercialization of cardiovascular medicines. The company is headquartered in Montreal, Quebec and currently employs 33 full-time employees. The company went IPO on 2019-05-09. The firm is focused on the development and commercialization of cardiovascular medicines. Its lead product candidate, etripamil, is a potent rapid-onset calcium channel blocker that the Company designed and is developing as a rapid-onset nasal spray to be administered by patients. The firm is also focused on developing etripamil to treat paroxysmal supraventricular tachycardia, atrial fibrillation, and other cardiovascular indications.
What is the current price of MIST stock?
The current stock price of MIST is 2.06 USD. The price increased by 3% in the last trading session.
Does MIST stock pay dividends?
MIST does not pay a dividend.
How is the ChartMill rating for MILESTONE PHARMACEUTICALS IN?
MIST has a ChartMill Technical rating of 7 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of MILESTONE PHARMACEUTICALS IN (MIST) based on its PE ratio?
MILESTONE PHARMACEUTICALS IN (MIST) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.83).
What is MILESTONE PHARMACEUTICALS IN worth?
MILESTONE PHARMACEUTICALS IN (MIST) has a market capitalization of 175.08M USD. This makes MIST a Micro Cap stock.
When does MILESTONE PHARMACEUTICALS IN (MIST) report earnings?
MILESTONE PHARMACEUTICALS IN (MIST) will report earnings on 2026-03-11, after the market close.
MIST Technical Analysis
ChartMill assigns a technical rating of 7 / 10 to MIST. When comparing the yearly performance of all stocks, MIST is one of the better performing stocks in the market, outperforming 82.21% of all stocks.
MIST Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to MIST. MIST may be in some trouble as it scores bad on both profitability and health.
MIST Financial Highlights
Over the last trailing twelve months MIST reported a non-GAAP Earnings per Share(EPS) of -0.83. The EPS decreased by -2.35% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -117.11% | ||
| ROE | N/A | ||
| Debt/Equity | N/A |
MIST Forecast & Estimates
11 analysts have analysed MIST and the average price target is 3.83 USD. This implies a price increase of 85.68% is expected in the next year compared to the current price of 2.06.